Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annexon Inc (NQ: ANNX )

2.950 -0.050 (-1.67%)
Streaming Delayed Price Updated: 11:13 AM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 489,550
Open 3.000
Bid (Size) 2.950 (298)
Ask (Size) 2.960 (3)
Prev. Close 3.000
Today's Range 2.920 - 3.120
52wk Range 2.070 - 7.650
Shares Outstanding 47,722,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2023
 
Via Benzinga

Performance

YTD
-38.41%
-38.41%
1 Month
-39.55%
-39.55%
3 Month
-41.58%
-41.58%
6 Month
-46.56%
-46.56%
1 Year
-1.01%
-1.01%

More News

Read More
Crude Oil Drops Sharply; Best Buy Earnings Top Expectations
Via Benzinga
Analyst Expectations for Annexon's Future
Via Benzinga
Why Annexon (ANNX) Stock Is Getting Hammered
Via Benzinga
Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study
Via Benzinga
Analyst Ratings for Annexon
Via Benzinga
The Latest Analyst Ratings for Annexon
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Nasdaq Surges 1.5%; NVIDIA Shares Jump Following Strong Q1 Results
Via Benzinga
Why Shares of Annexon Are Plummeting Thursday
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
Via Benzinga
Dow Drops 100 Points; US GDP Tops Estimates
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
From Annexon Biosciences
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.